MAI Capital Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.66M | Buy |
31,603
+3,647
| +13% | +$193K | 0.01% | 764 |
|
|
2026
Q1 | $1.54M | Buy |
27,956
+499
| +2% | +$27K | 0.01% | 649 |
|
|
2025
Q4 | $1.35M | Sell |
27,457
-524
| -2% | -$24.4K | 0.01% | 664 |
|
|
2025
Q3 | $1.21M | Sell |
27,981
-1,404
| -5% | -$54.8K | 0.01% | 655 |
|
|
2025
Q2 | $1.13M | Buy |
29,385
+3,110
| +12% | +$119K | 0.01% | 619 |
|
|
2025
Q1 | $1.02M | Buy |
26,275
+592
| +2% | +$21.7K | 0.01% | 617 |
|
|
2024
Q4 | $869K | Sell |
25,683
-1,545
| -6% | -$55.6K | 0.01% | 678 |
|
|
2024
Q3 | $1.11M | Sell |
27,228
-6,945
| -20% | -$284K | 0.01% | 525 |
|
|
2024
Q2 | $1.32M | Buy |
34,173
+1,025
| +3% | +$43.1K | 0.01% | 520 |
|
|
2024
Q1 | $1.42M | Buy |
33,148
+18,993
| +134% | +$783K | 0.01% | 477 |
|
|
2023
Q4 | $525K | Buy |
14,155
+27
| +0.2% | +$969 | 0.01% | 686 |
|
|
2023
Q3 | $512K | Sell |
14,128
-495
| -3% | -$17.6K | 0.01% | 639 |
|
|
2023
Q2 | $521K | Sell |
14,623
-727
| -5% | -$26.1K | 0.01% | 621 |
|
|
2023
Q1 | $546K | Buy |
15,350
+1,402
| +10% | +$49K | 0.01% | 608 |
|
|
2022
Q4 | $490K | Buy |
+13,948
| New | +$465K | 0.01% | 621 |
|
|
2022
Q3 | – | Sell |
-7,345
| Closed | -$400K | – | 985 |
|
|
2022
Q2 | $400K | Sell |
7,345
-1,200
| -14% | -$66.2K | 0.01% | 611 |
|
|
2022
Q1 | $465K | Buy |
+8,545
| New | +$464K | 0.01% | 584 |
|
|
2016
Q4 | – | Sell |
-4,604
| Closed | -$248K | – | 450 |
|
|
2016
Q3 | $248K | Hold |
4,604
| – | – | 0.02% | 373 |
|
|
2016
Q2 | $249K | Sell |
4,604
-551
| -11% | -$29K | 0.02% | 351 |
|
|
2016
Q1 | $261K | Sell |
5,155
-142
| -3% | -$7.07K | 0.02% | 341 |
|
|
2015
Q4 | $267K | Sell |
5,297
-520
| -9% | -$26.5K | 0.02% | 341 |
|
|
2015
Q3 | $280K | Sell |
5,817
-1,617
| -22% | -$84.2K | 0.02% | 352 |
|
|
2015
Q2 | $387K | Sell |
7,434
-718
| -9% | -$40.4K | 0.03% | 340 |
|
|
2015
Q1 | $470K | Sell |
8,152
-1,999
| -20% | -$115K | 0.03% | 312 |
|
|
2014
Q4 | $542K | Sell |
10,151
-151,518
| -94% | -$8.48M | 0.04% | 287 |
|
|
2014
Q3 | $9.29M | Buy |
161,669
+1,599
| +1% | +$98K | 0.9% | 37 |
|
|
2014
Q2 | $10.7M | Sell |
160,070
-13,440
| -8% | -$910K | 1.03% | 36 |
|
|
2014
Q1 | $11.6M | Sell |
173,510
-1,694
| -1% | -$115K | 1.17% | 28 |
|
|
2013
Q4 | $11.7M | Buy |
175,204
+7,012
| +4% | +$455K | 1.24% | 25 |
|
|
2013
Q3 | $10.5M | Buy |
168,192
+5,637
| +3% | +$363K | 1.37% | 25 |
|
|
2013
Q2 | $10.2M | Buy |
+162,555
| New | +$10.3M | 1.32% | 26 |
|
Other funds holding GSK
JEST
MAI Capital Management's GSK Position: Q2 2026 in Review
MAI Capital Management increased its GSK (GSK) stake by 13% in Q2 2026, buying an estimated $193K and bringing the position to 31,603 shares worth $1.66M. The position accounts for 0.01% of the portfolio, ranked #764.
MAI Capital Management first reported a position in GSK in Q2 2013 and has held it in 31 quarters since. The position peaked at $11.7M in Q4 2013. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- MAI Capital Management held 31,603 shares of GSK worth $1.66M as of Q2 2026.
- MAI Capital Management bought 3,647 GSK shares in Q2 2026, an estimated $193K.
- GSK made up 0.01% of MAI Capital Management's portfolio in Q2 2026, its #764 holding.
- MAI Capital Management first reported a position in GSK in Q2 2013 and has held it in 31 quarters since.
- MAI Capital Management's GSK position peaked at $11.7M in Q4 2013.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.